ITGAX and non-small cell lung carcinoma: Additionally, ITGAL, ITGAX, and TMEM119 effectively predicted NSCLC response to ICB therapy both individually and as a panel (Figure 3C; Figure S2C–E), which was not the situation for PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN.